Trials / Completed
CompletedNCT00969150
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 362 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levomilnacipran ER | Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks. |
| DRUG | Placebo | Matching placebo to be given orally, in capsule form, once daily, for 8 weeks. |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-11-01
- First posted
- 2009-09-01
- Last updated
- 2013-10-25
- Results posted
- 2013-10-25
Locations
25 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00969150. Inclusion in this directory is not an endorsement.